Literature DB >> 17962513

Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors.

Rangaiah Shashidharamurthy1, Randolph A Hennigar, Sebastien Fuchs, Purani Palaniswami, Melanie Sherman, Periasamy Selvaraj.   

Abstract

Extravasation and emigration of neutrophils to the site of inflammation are essential early steps in the initiation of many antibody-mediated autoimmune diseases. The Fc domains of cell bound autoantibodies or immune-complexes (IC) are capable of triggering the neutrophil emigration via complement and FcgammaRs-mediated mechanisms. To define the clinical relevance and the relative contribution of these 2 pathways in IC-mediated neutrophil emigration, we have neutralized the FcgammaR-binding activity of IC with a recombinant dimeric Fc receptor, CD16A-Ig, and investigated the early events of IC-induced inflammation in mice. Systemic administration of purified CD16A-Ig blocked IC-induced inflammation, mast- cell degranulation, and extravasation of neutrophils in a reversed Arthus reaction. Although the binding of CD16A-Ig to IC did not alter the complement-activating properties of IC, no evidence for complement-dependent neutrophil emigration was observed. These results suggest that interaction of IC with cells expressing FcgammaRs at the inflammatory site results in the secretion of chemoattractants, which mediate complement-independent emigration of neutrophils in this cutaneous acute inflammation model. Furthermore, blocking the interaction of IC to FcgammaRs expressed on inflammatory cells by administering high-avidity Fc fusion dimers of low-affinity FcgammaRs is an effective way of preventing IC-induced acute inflammation in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962513      PMCID: PMC2200857          DOI: 10.1182/blood-2007-04-085944

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

Authors:  R P Junghans; C L Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

2.  A dominant role for mast cell Fc receptors in the Arthus reaction.

Authors:  D L Sylvestre; J V Ravetch
Journal:  Immunity       Date:  1996-10       Impact factor: 31.745

3.  Neutrophil elicitation in the reverse passive Arthus reaction. Complement-dependent and -independent mast cell involvement.

Authors:  B F Ramos; Y Zhang; B A Jakschik
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

4.  Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade.

Authors:  D L Sylvestre; J V Ravetch
Journal:  Science       Date:  1994-08-19       Impact factor: 47.728

5.  Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice.

Authors:  W L Hazenbos; J E Gessner; F M Hofhuis; H Kuipers; D Meyer; I A Heijnen; R E Schmidt; M Sandor; P J Capel; M Daëron; J G van de Winkel; J S Verbeek
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

6.  Flow cytometric quantitation of attachment and phagocytosis in phenotypically-defined subpopulations of cells using PKH26-labeled Fc gamma R-specific probes.

Authors:  L Pricop; J E Salmon; J C Edberg; A J Beavis
Journal:  J Immunol Methods       Date:  1997-06-23       Impact factor: 2.303

7.  Neurogenic amplification of immune complex inflammation.

Authors:  C R Bozic; B Lu; U E Höpken; C Gerard; N P Gerard
Journal:  Science       Date:  1996-09-20       Impact factor: 47.728

8.  Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells.

Authors:  S Nagarajan; S Chesla; L Cobern; P Anderson; C Zhu; P Selvaraj
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

9.  Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength.

Authors:  D H Jones; R J Looney; C L Anderson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice.

Authors:  D Sylvestre; R Clynes; M Ma; H Warren; M C Carroll; J V Ravetch
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

View more
  12 in total

1.  Hsp60 and Hsp10 increase in colon mucosa of Crohn’s disease and ulcerative colitis.

Authors:  Vito Rodolico; Giovanni Tomasello; Monica Zerilli; Anna Martorana; Alessandro Pitruzzella; Antonella Marino Gammazza; Sabrina David; Giovanni Zummo; Provvidenza Damiani; Salvatore Accomando; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello
Journal:  Cell Stress Chaperones       Date:  2010-11       Impact factor: 3.667

2.  Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection.

Authors:  Andreas Wieland; Rangaiah Shashidharamurthy; Alice O Kamphorst; Jin-Hwan Han; Rachael D Aubert; Biswa P Choudhury; Sean R Stowell; Junghwa Lee; George A Punkosdy; Mark J Shlomchik; Periasamy Selvaraj; Rafi Ahmed
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

Review 3.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

4.  Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A.

Authors:  Rangaiah Shashidharamurthy; Fang Zhang; Aaron Amano; Aparna Kamat; Ravichandran Panchanathan; Daniel Ezekwudo; Cheng Zhu; Periasamy Selvaraj
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  When is a malaria immune complex not an immune complex?

Authors:  R J Pleass
Journal:  Parasite Immunol       Date:  2009-02       Impact factor: 2.280

6.  Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice.

Authors:  Rangaiah Shashidharamurthy; Deepa Machiah; Jesse D Aitken; Kalyani Putty; Gayathri Srinivasan; Benoit Chassaing; Charles A Parkos; Periasamy Selvaraj; Matam Vijay-Kumar
Journal:  Arthritis Rheum       Date:  2013-04

Review 7.  Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis.

Authors:  Maurizio Bellavia; Giovanni Tomasello; Marcello Romeo; Provvidenza Damiani; Attilio I Lo Monte; Luciano Lozio; Claudia Campanella; Antonella Marino Gammazza; Francesca Rappa; Giovanni Zummo; Massimo Cocchi; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello
Journal:  Med Microbiol Immunol       Date:  2013-07-18       Impact factor: 3.402

8.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

9.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

10.  Does activation of the FcgammaRIIa play a role in the pathogenesis of the acute lung injury/acute respiratory distress syndrome?

Authors:  Rafal Fudala; Agnieszka Krupa; Dorota Stankowska; Timothy C Allen; Anna K Kurdowska
Journal:  Clin Sci (Lond)       Date:  2010-01-26       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.